

Kimberly H Allison

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/3245812/publications.pdf](https://exaly.com/author-pdf/3245812/publications.pdf)

Version: 2024-02-01

80
papers

12,656
citations

127545

33
h-index

85929

71
g-index

80
all docs

80
docs citations

80
times ranked

16493
citing authors

#	ARTICLE	IF	CITATIONS
1	Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2013, 31, 3997-4013.	1.7	3,276
2	Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. <i>Cell</i> , 2015, 163, 506-519.	29.2	1,485
3	Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2105-2122.	1.7	1,362
4	Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 241-256.	2.5	961
5	Extracellular matrix stiffness and composition jointly regulate the induction of malignant phenotypes in mammary epithelium. <i>Nature Materials</i> , 2014, 13, 970-978.	28.1	689
6	Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 1346-1366.	1.7	673
7	Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 1364-1382.	2.5	644
8	Diagnostic Concordance Among Pathologists Interpreting Breast Biopsy Specimens. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1122.	7.5	499
9	The 2019 World Health Organization classification of tumours of the breast. <i>Histopathology</i> , 2020, 77, 181-185.	2.9	395
10	Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 545-563.	2.5	205
11	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immunotherapy biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	4.5	142
12	Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 1816-1837.	1.7	139
13	HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary. <i>Journal of Oncology Practice</i> , 2018, 14, 437-441.	2.5	111
14	Angiosarcoma Involving the Gastrointestinal Tract. <i>American Journal of Surgical Pathology</i> , 2004, 28, 298-307.	3.7	110
15	Frequency and Upgrade Rates of Atypical Ductal Hyperplasia Diagnosed at Stereotactic Vacuum-Assisted Breast Biopsy: 9-Versus 11-Gauge. <i>American Journal of Roentgenology</i> , 2009, 192, 229-234.	2.2	99
16	Molecular Pathology of Breast Cancer. <i>American Journal of Clinical Pathology</i> , 2012, 138, 770-780.	0.7	91
17	The molecular basis of breast cancer pathological phenotypes. <i>Journal of Pathology</i> , 2017, 241, 375-391.	4.5	86
18	Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases. <i>JAMA Oncology</i> , 2017, 3, 969.	7.2	84

#	ARTICLE	IF	CITATIONS
19	Diagnosing Endometrial Hyperplasia. <i>American Journal of Surgical Pathology</i> , 2008, 32, 691-698.	3.7	82
20	Understanding diagnostic variability in breast pathology: lessons learned from an expert consensus review panel. <i>Histopathology</i> , 2014, 65, 240-251.	2.9	81
21	Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations. <i>Journal of Clinical Oncology</i> , 2016, 34, 2303-2311.	1.7	80
22	“Non-classical” HER2 FISH results in breast cancer: a multi-institutional study. <i>Modern Pathology</i> , 2017, 30, 227-235.	5.5	79
23	Frequency of HER2 Heterogeneity by Fluorescence In Situ Hybridization According to CAP Expert Panel Recommendations. <i>American Journal of Clinical Pathology</i> , 2011, 136, 864-871.	0.7	78
24	Eye Movements as an Index of Pathologist Visual Expertise: A Pilot Study. <i>PLoS ONE</i> , 2014, 9, e103447.	2.5	77
25	Atypical ductal hyperplasia on vacuum-assisted breast biopsy: suspicion for ductal carcinoma in situ can stratify patients at high risk for upgrade†. <i>Human Pathology</i> , 2011, 42, 41-50.	2.0	59
26	Achieving 95% Cross-Methodological Concordance in HER2 Testing. <i>American Journal of Clinical Pathology</i> , 2010, 134, 284-292.	0.7	57
27	Epithelioid Trophoblastic Tumor: Review of a Rare Neoplasm of the Chorionic-Type Intermediate Trophoblast. <i>Archives of Pathology and Laboratory Medicine</i> , 2006, 130, 1875-1877.	2.5	55
28	Variability in Pathologists' Interpretations of Individual Breast Biopsy Slides: A Population Perspective. <i>Annals of Internal Medicine</i> , 2016, 164, 649.	4.0	52
29	Quantitative Image Analysis of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry for Breast Cancer: Guideline From the College of American Pathologists. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 1180-1195.	2.5	49
30	Trends in breast biopsy pathology diagnoses among women undergoing mammography in the United States: A report from the Breast Cancer Surveillance Consortium. <i>Cancer</i> , 2015, 121, 1369-1378.	4.1	44
31	Development of a diagnostic test set to assess agreement in breast pathology: practical application of the Guidelines for Reporting Reliability and Agreement Studies (GRRAS). <i>BMC Women's Health</i> , 2013, 13, 3.	2.0	42
32	Optimized Protocol for Quantitative Multiple Reaction Monitoring-Based Proteomic Analysis of Formalin-Fixed, Paraffin-Embedded Tissues. <i>Journal of Proteome Research</i> , 2016, 15, 2717-2728.	3.8	42
33	Molecular analysis of TCGA breast cancer histologic types. <i>Cell Genomics</i> , 2021, 1, 100067.	6.7	37
34	Breast cancer stem cells: are we ready to go from bench to bedside?. <i>Histopathology</i> , 2016, 68, 119-137.	2.9	35
35	DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome Atlas. <i>Npj Breast Cancer</i> , 2016, 2, 16007.	5.3	33
36	Updates on breast biomarkers. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 163-176.	2.8	33

#	ARTICLE	IF	CITATIONS
37	The diagnostic challenge of low-grade ductal carcinoma in situ. <i>European Journal of Cancer</i> , 2017, 80, 39-47.	2.9	32
38	Reply to E.A. Rakha et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 1302-1304.	1.7	31
39	Pretreatment Tattoo Marking of Suspicious Axillary Lymph Nodes: Reliability and Correlation with Sentinel Lymph Node. <i>Annals of Surgical Oncology</i> , 2019, 26, 2452-2458.	1.6	30
40	Second opinion in breast pathology: policy, practice and perception. <i>Journal of Clinical Pathology</i> , 2014, 67, 955-960.	2.0	29
41	Quantification of Human Epidermal Growth Factor Receptor 2 by Immunopeptide Enrichment and Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded and Frozen Breast Cancer Tissues. <i>Clinical Chemistry</i> , 2021, 67, 1008-1018.	3.2	29
42	A Randomized Study Comparing Digital Imaging to Traditional Glass Slide Microscopy for Breast Biopsy and Cancer Diagnosis. <i>Journal of Pathology Informatics</i> , 2017, 8, 12.	1.7	28
43	Characteristics and clinical outcomes of pleomorphic lobular carcinoma in situ of the breast. <i>Breast Journal</i> , 2018, 24, 66-69.	1.0	25
44	Superficial Malignant Peripheral Nerve Sheath Tumor. <i>American Journal of Clinical Pathology</i> , 2005, 124, 685-692.	0.7	25
45	Evaluation of 12 strategies for obtaining second opinions to improve interpretation of breast histopathology: simulation study. <i>BMJ, The</i> , 2016, 353, i3069.	6.1	24
46	Second opinion strategies in breast pathology: a decision analysis addressing over-treatment, under-treatment, and care costs. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 195-203.	2.5	24
47	Immunohistochemical Markers in Endometrial Hyperplasia: Is There a Panel With Promise?. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2008, 16, 329-343.	1.3	20
48	Defining an Appropriate Threshold for the Diagnosis of Serous Borderline Tumor of the Ovary. <i>International Journal of Gynecological Pathology</i> , 2008, 27, 10-17.	1.5	19
49	Diagnostic Reproducibility: What Happens When the Same Pathologist Interprets the Same Breast Biopsy Specimen at Two Points in Time?. <i>Annals of Surgical Oncology</i> , 2017, 24, 1234-1241.	1.6	19
50	Breast cancer prognostic factors in the digital era: Comparison of Nottingham grade using whole slide images and glass slides. <i>Journal of Pathology Informatics</i> , 2019, 10, 11.	1.7	19
51	An Unusual Case of Multiple Giant Myelolipomas: Clinical and Pathogenetic Implications. <i>Endocrine Pathology</i> , 2003, 14, 93-100.	9.4	17
52	Preoperative MRI Improves Prediction of Extensive Occult Axillary Lymph Node Metastases in Breast Cancer Patients with a Positive Sentinel Lymph Node Biopsy. <i>Academic Radiology</i> , 2014, 21, 92-98.	2.5	17
53	Rosai-Dorfman Disease of the Breast With Variable IgG4+ Plasma Cells. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1653-1660.	3.7	17
54	ERBB2-Low Breast Cancer—Is It a Fact or Fiction, and Do We Have the Right Assay?. <i>JAMA Oncology</i> , 2022, 8, 610.	7.2	17

#	ARTICLE	IF	CITATIONS
55	Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis. <i>Modern Pathology</i> , 2020, 33, 1518-1526.	5.5	16
56	Histological features associated with diagnostic agreement in atypical ductal hyperplasia of the breast: illustrative cases from the B&P Path study. <i>Histopathology</i> , 2016, 69, 1028-1046.	2.9	15
57	Pupil diameter changes reflect difficulty and diagnostic accuracy during medical image interpretation. <i>BMC Medical Informatics and Decision Making</i> , 2016, 16, 77.	3.0	15
58	Will oncotype DX DCIS testing guide therapy? A single-institution correlation of oncotype DX DCIS results with histopathologic findings and clinical management decisions. <i>Modern Pathology</i> , 2018, 31, 562-568.	5.5	15
59	Surgical implications and variability in the use of the flat epithelial atypia diagnosis on breast biopsy specimens. <i>Breast</i> , 2017, 34, 34-43.	2.2	14
60	Prognostic and predictive parameters in breast pathology: a pathologist's primer. <i>Modern Pathology</i> , 2021, 34, 94-106.	5.5	14
61	Nodular fasciitis of the breast: clinicopathologic and molecular characterization with identification of novel USP6 fusion partners. <i>Modern Pathology</i> , 2021, 34, 1865-1875.	5.5	13
62	Integrated genomic characterization of ERBB2/HER2 alterations in invasive breast carcinoma: a focus on unusual FISH groups. <i>Modern Pathology</i> , 2020, 33, 1546-1556.	5.5	12
63	Identifying and processing the gap between perceived and actual agreement in breast pathology interpretation. <i>Modern Pathology</i> , 2016, 29, 717-726.	5.5	10
64	Estrogen Receptor Expression in Breast Cancer. <i>American Journal of Clinical Pathology</i> , 2008, 130, 853-854.	0.7	9
65	Regional Variability in Percentage of Breast Cancers Reported as Positive for HER2 in California. <i>American Journal of Clinical Pathology</i> , 2017, 148, 199-207.	0.7	9
66	The Influence of Disease Severity of Preceding Clinical Cases on Pathologists'™ Medical Decision Making. <i>Medical Decision Making</i> , 2017, 37, 91-100.	2.5	8
67	Ancillary Prognostic and Predictive Testing in Breast Cancer. <i>Surgical Pathology Clinics</i> , 2018, 11, 147-176.	1.7	6
68	Characteristics associated with requests by pathologists for second opinions on breast biopsies. <i>Journal of Clinical Pathology</i> , 2017, 70, 947-953.	2.0	4
69	HER2 Dual In Situ Hybridization: Correlations and Cautions. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 1525-1534.	2.5	4
70	HER2 Testing. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, Publish Ahead of Print, 635-642.	1.3	2
71	The Milky Way Sign: A New Diagnostic Finding of Ductal Carcinoma in Situ on Digital Breast Tomosynthesis. <i>Breast Journal</i> , 2016, 22, 349-351.	1.0	1
72	Reply to C. Murray et al and V. Martin et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 3524-3525.	1.7	1

#	ARTICLE	IF	CITATIONS
73	Interview: Breast cancer: the pathologist's point of view. Breast Cancer Management, 2013, 2, 363-366.	0.2	0
74	Introduction to "Non-Epithelial Lesions of the Breast" Issue. Seminars in Diagnostic Pathology, 2017, 34, 399.	1.5	0
75	In Reply. Archives of Pathology and Laboratory Medicine, 2019, 143, 413-414.	2.5	0
76	Surgical Excision Versus Neoadjuvant Radiotherapy Followed by Delayed Surgical Excision of Ductal Carcinoma In Situ (NORDIS). Annals of Surgical Oncology, 2021, , 1.	1.6	0
77	Tissue sampling frequency and breast pathology diagnoses following mammography: Time trends and age group analysis from the Breast Cancer Surveillance Consortium (BCSC).. Journal of Clinical Oncology, 2013, 31, 559-559.	1.7	0
78	Intraductal Proliferations (DCIS, ADH, and UDH). , 2016, , 337-375.		0
79	The Importance of Addressing Diagnostic Challenges in Breast Pathology with an Understanding of Current Clinical Treatment Implications. Surgical Pathology Clinics, 2022, 15, xi-xii.	1.7	0
80	Abstract OT1-09-01: A randomized study comparing surgical excision versus neoadjuvant radiotherapy followed by delayed surgical excision of ductal carcinoma in situ (NORDIS). Cancer Research, 2022, 82, OT1-09-01-OT1-09-01.	0.9	0